Overview
Sponsor-declared trial summary
Atherosclerotic cardiovascular disease (ASCVD)
Demonstrate the superiority of inclisiran compared to placebo in reducing the risk of 3P-MACE (composite of CV death, non-fatal MI and non-fatal ischemic stroke) in participants with established ASCVD and a LDL-C ≥1.8 mmol/L (70 mg/dL).
Key facts
- Sponsor
- Novartis Pharma AG
- Participant type
- Patients
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Cardiovascular Diseases [C14]
- Trial duration
- 26 Nov 2021 → ongoing
- Decision date (initial)
- 2024-07-02
- Transition trial
- Yes
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- Yes
- Funding sources
- Novartis Pharma AG
External identifiers
- EU CT number
- 2024-510735-21-00
- EudraCT number
- 2021-002006-27
- ClinicalTrials.gov
- NCT05030428
Trial design
CTIS Part I — objectives, methods, condition coding
Main objective
Scope: Therapy, Pharmacogenomic, Efficacy, Safety
Demonstrate the superiority of inclisiran compared to placebo in reducing the risk of 3P-MACE (composite of CV death, non-fatal MI and non-fatal ischemic stroke) in participants with established ASCVD and a LDL-C ≥1.8 mmol/L (70 mg/dL).
Secondary objectives 5
- To demonstrate the superiority of inclisiran compared to placebo in reducing the risk of cardiovascular death
- To demonstrate the superiority of inclisiran compared to placebo in reducing the risk of 4P-MACE (composite of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, and urgent coronary revascularization)
- To demonstrate the superiority of inclisiran compared to placebo in reducing the risk of major adverse limb events (MALE)
- To demonstrate the superiority of inclisiran compared to placebo in reducing the risk of all-cause death
- To evaluate the safety and tolerability of inclisiran compared to placebo
Conditions and MedDRA coding
Atherosclerotic cardiovascular disease (ASCVD)
| Version | Level | Code | Term | System organ class |
|---|---|---|---|---|
| 26.0 | LLT | 10051615 | Atherosclerotic cardiovascular disease | 10047065 |
Eligibility criteria
Principal inclusion / exclusion criteria as submitted by sponsor
Inclusion criteria 4
- Male or female ≥40 years of age
- Fasting LDL-C ≥1.8 mmol/L (70 mg/dL) at the Screening Visit
- At the Screening Visit, participants must be on a stable (≥4 weeks) and well-tolerated lipid-lowering regimen (including e.g., with or without Ezetimibe) that must include a high-intensity statin therapy with either atorvastatin ≥40 mg QD or rosuvastatin ≥20 mg QD
- Established CV disease, defined as any of the following: - Previous myocardial infarction - Previous ischemic stroke - Symptomatic peripheral arterial disease (PAD), as evidenced by either intermittent claudication with ABI <0.85, prior peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease
Exclusion criteria 4
- New York Heart Association (NYHA) class III or IV heart failure at the Statin Optimization Screening Visit (if applicable), Screening Visit, or at the Baseline Visit (Day1)
- Previous exposure to inclisiran or any other non-mAb PCSK9-targeted therapy, either as an investigational or marketed drug within 2 years prior to the first study visit
- Pregnant or nursing (lactating) women
- Women of child-bearing potential, unless they are using effective methods of contraception during dosing of study treatment
Endpoints
Primary and secondary outcome measures (English text)
Primary endpoints 1
- Time to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal ischemic stroke (3P-MACE)
Secondary endpoints 6
- Time to cardiovascular death
- Time to first occurrence of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, or urgent coronary revascularization (4P-MACE)
- Time to fist occurrence of Major Adverse Limb Events (MALE)
- Time to all-cause death
- Number of participants with SAEs
- Number of participants with AEs leading to study treatment discontinuation
Investigational products
Investigational medicinal products (IMPs), comparators, placebo, auxiliary
Test 1
SUB182427 · Substance
- Active substance
- Inclisiran
- Pharmaceutical form
- SOLUTION FOR INJECTION
- Route of administration
- SUBCUTANEOUS USE
- Max daily dose
- 300 mg milligram(s)
- Max total dose
- 3900 mg milligram(s)
- Max treatment duration
- 72 Month(s)
- Authorisation status
- Authorised
- ATC code
- - — -
- Marketing authorisation
- -
- Paediatric formulation
- No
- Orphan designation
- No
- Modified vs. Marketing Authorisation
- Yes
- Modification description
- The clinical dossier contains alternative packaging sites for supplies for clinical trials which are not included in the MA dossier. The drug substance retest period in the MA dossier is 36 months. The drug product shelf life in the MA dossier is 36 months.
Placebo 1
Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe
N/A · Product
- Other product name
- N/A
- Pharmaceutical form
- N/A
- ATC code
- N/A — N/A
- Marketing authorisation
- N/A
- MA holder
- N/A
- MA country
- Iceland
- Paediatric formulation
- No
Auxiliary 8
SUB05600MIG · Substance
- Active substance
- Atorvastatin
- Pharmaceutical form
- TABLET
- Route of administration
- ORAL USE
- Max daily dose
- 40 mg milligram(s)
- Max total dose
- 175200 mg milligram(s)
- Max treatment duration
- 72 Month(s)
- Authorisation status
- Authorised
- ATC code
- - — -
- Marketing authorisation
- -
- Paediatric formulation
- No
- Orphan designation
- No
- Modified vs. Marketing Authorisation
- No
SUB05600MIG · Substance
- Active substance
- Atorvastatin
- Pharmaceutical form
- TABLET
- Route of administration
- ORAL USE
- Max daily dose
- 40 mg milligram(s)
- Max total dose
- 175200 mg milligram(s)
- Max treatment duration
- 72 Month(s)
- Authorisation status
- Authorised
- ATC code
- - — -
- Marketing authorisation
- -
- Paediatric formulation
- No
- Orphan designation
- No
- Modified vs. Marketing Authorisation
- No
SUB05600MIG · Substance
- Active substance
- Atorvastatin
- Pharmaceutical form
- TABLET
- Route of administration
- ORAL USE
- Max daily dose
- 40 mg milligram(s)
- Max total dose
- 175200 mg milligram(s)
- Max treatment duration
- 72 Month(s)
- Authorisation status
- Authorised
- ATC code
- - — -
- Marketing authorisation
- -
- Paediatric formulation
- No
- Orphan designation
- No
- Modified vs. Marketing Authorisation
- No
SUB05600MIG · Substance
- Active substance
- Atorvastatin
- Pharmaceutical form
- TABLET
- Route of administration
- ORAL USE
- Max daily dose
- 40 mg milligram(s)
- Max total dose
- 175200 mg milligram(s)
- Max treatment duration
- 72 Month(s)
- Authorisation status
- Authorised
- ATC code
- - — -
- Marketing authorisation
- -
- Paediatric formulation
- No
- Orphan designation
- No
- Modified vs. Marketing Authorisation
- No
SUB20634 · Substance
- Active substance
- Rosuvastatin
- Pharmaceutical form
- TABLET
- Route of administration
- ORAL USE
- Max daily dose
- 40 mg milligram(s)
- Max total dose
- 87640 mg milligram(s)
- Max treatment duration
- 72 Month(s)
- Authorisation status
- Authorised
- ATC code
- - — -
- Marketing authorisation
- -
- Paediatric formulation
- No
- Orphan designation
- No
- Modified vs. Marketing Authorisation
- No
SUB20634 · Substance
- Active substance
- Rosuvastatin
- Pharmaceutical form
- TABLET
- Route of administration
- ORAL USE
- Max daily dose
- 40 mg milligram(s)
- Max total dose
- 87640 mg milligram(s)
- Max treatment duration
- 72 Month(s)
- Authorisation status
- Authorised
- ATC code
- - — -
- Marketing authorisation
- -
- Paediatric formulation
- No
- Orphan designation
- No
- Modified vs. Marketing Authorisation
- No
SUB20634 · Substance
- Active substance
- Rosuvastatin
- Pharmaceutical form
- TABLET
- Route of administration
- ORAL USE
- Max daily dose
- 40 mg milligram(s)
- Max total dose
- 87640 mg milligram(s)
- Max treatment duration
- 72 Month(s)
- Authorisation status
- Authorised
- ATC code
- - — -
- Marketing authorisation
- -
- Paediatric formulation
- No
- Orphan designation
- No
- Modified vs. Marketing Authorisation
- No
SUB20634 · Substance
- Active substance
- Rosuvastatin
- Pharmaceutical form
- TABLET
- Route of administration
- ORAL USE
- Max daily dose
- 40 mg milligram(s)
- Max total dose
- 87640 mg milligram(s)
- Max treatment duration
- 72 Month(s)
- Authorisation status
- Authorised
- ATC code
- - — -
- Marketing authorisation
- -
- Paediatric formulation
- No
- Orphan designation
- No
- Modified vs. Marketing Authorisation
- No
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Novartis Pharma AG
- Sponsor organisation
- Novartis Pharma AG
- Address
- Lichtstrasse 35
- City
- Basel
- Postcode
- 4056
- Country
- Switzerland
Scientific contact point
- Organisation
- Novartis Pharma AG
- Contact name
- Novartis Pharma Arzneimittel GmbH
Public contact point
- Organisation
- Novartis Pharma AG
- Contact name
- Novartis Pharma Arzneimittel GmbH
Third parties 27
| Organisation | City, country | Duties |
|---|---|---|
| Medidata Solutions Inc. ORG-100016256
|
New York, United States | Data management |
| Greenphire LLC ORG-100041621
|
King Of Prussia, United States | Other |
| Tamro Oyj ORG-100011802
|
Vantaa, Finland | Other |
| IQVIA RDS Spain S.L. ORG-100014508
|
Madrid, Spain | On site monitoring |
| Mag. Andreas Raffeiner GmbH ORG-100043223
|
Walding, Austria | Code 8 |
| Omnitrace Corp. ORG-100045579
|
Palm Beach Gardens, United States | Other |
| Abf Pharmaceutical Services GmbH ORG-100014752
|
Vienna, Austria | Other |
| IQVIA Limited ORG-100008655
|
Reading, United Kingdom | On site monitoring, Other, Interactive response technologies (IRT) |
| Datacubed Health Inc. ORG-100047227
|
King Of Prussia, United States | Other |
| Movianto Slovensko s.r.o. ORG-100020628
|
Senec, Slovakia | Other |
| Creapharm Clinical Supplies ORG-100020131
|
Le Haillan, France | Other |
| Opis S.r.l. ORG-100011127
|
Desio, Italy | Other |
| Mipharm S.p.A. ORG-100000724
|
Milan, Italy | Other |
| Distica hf. ORG-100022309
|
Gardabaer, Iceland | Other |
| Medpace Reference Laboratories LLC ORG-100041727
|
Cincinnati, United States | Laboratory analysis |
| Oribalt Riga SIA ORG-100012153
|
Marupe, Latvia | Other |
| Syneos Health Inc. ORG-100008382
|
Morrisville, United States | On site monitoring |
| PRA Hellas CRO A.E. ORG-100048208
|
Nea Ionia, Greece | On site monitoring |
| Icon Laboratory Services Inc. ORG-100037135
|
Farmingdale, United States | Laboratory analysis |
| Parexel International (IRL) Limited ORG-100022780
|
Dublin 2, Ireland | On site monitoring, Code 12, Code 2, Code 5 |
| Cleveland Clinic Foundation ORG-100028017
|
Cleveland, United States | Other |
| Medical Intertrade d.o.o. ORG-100001426
|
Sveta Nedelja, Croatia | Other |
| Freja Transport & Logistics AS ORG-100018845
|
Frogner, Norway | Other |
| Icon Clinical Research Limited ORG-100008322
|
Dublin 18, Ireland | On site monitoring |
| Syneos Health Clinical Spain S.L. ORG-100009277
|
Madrid, Spain | On site monitoring |
| WCG Clinical Inc. ORG-100040730
|
Washington, United States | Code 10 |
| Rps Research Iberica S.L. ORG-100030199
|
Barcelona, Spain | On site monitoring |
Locations
24 EU/EEA countries · 385 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Austria | Ongoing, recruitment ended | 8 | 2 |
| Belgium | Ongoing, recruitment ended | 138 | 14 |
| Bulgaria | Ongoing, recruitment ended | 638 | 29 |
| Croatia | Ongoing, recruitment ended | 215 | 17 |
| Czechia | Ongoing, recruitment ended | 584 | 27 |
| Denmark | Ongoing, recruitment ended | 120 | 9 |
| Estonia | Ongoing, recruitment ended | 67 | 8 |
| Finland | Ongoing, recruitment ended | 53 | 5 |
| France | Ongoing, recruitment ended | 296 | 32 |
| Greece | Ongoing, recruitment ended | 53 | 7 |
| Hungary | Ongoing, recruitment ended | 427 | 20 |
| Iceland | Ongoing, recruitment ended | 54 | 2 |
| Italy | Ongoing, recruitment ended | 142 | 17 |
| Latvia | Ongoing, recruitment ended | 83 | 8 |
| Lithuania | Ongoing, recruitment ended | 360 | 11 |
| Netherlands | Ongoing, recruitment ended | 646 | 22 |
| Norway | Ongoing, recruitment ended | 80 | 8 |
| Poland | Ongoing, recruitment ended | 874 | 26 |
| Portugal | Ongoing, recruitment ended | 231 | 12 |
| Romania | Ongoing, recruitment ended | 350 | 19 |
| Slovakia | Ongoing, recruitment ended | 494 | 26 |
| Slovenia | Ongoing, recruitment ended | 31 | 5 |
| Spain | Ongoing, recruitment ended | 684 | 50 |
| Sweden | Ongoing, recruitment ended | 145 | 9 |
| Rest of world
Philippines, Israel, Colombia, South Africa, Mauritius, Japan, India, Argentina, Chile, Malaysia, China, Turkey, Thailand, Brazil, Australia, Mexico, Serbia, United States, Taiwan, Kenya, Singapore, Canada, New Zealand, Korea, Republic of, Russian Federation
|
— | 10,234 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Austria | 2022-12-12 | 2022-12-12 | 2023-10-21 | ||
| Belgium | 2022-06-07 | 2022-06-07 | 2023-10-21 | ||
| Bulgaria | 2022-04-28 | 2022-04-28 | 2023-10-21 | ||
| Croatia | 2022-03-17 | 2022-03-17 | 2023-10-21 | ||
| Czechia | 2022-05-04 | 2022-05-04 | 2023-10-21 | ||
| Denmark | 2022-05-18 | 2022-05-18 | 2023-10-21 | ||
| Estonia | 2022-03-25 | 2022-03-25 | 2023-10-21 | ||
| Finland | 2022-06-09 | 2022-06-09 | 2023-10-21 | ||
| France | 2021-11-26 | 2021-11-26 | 2023-10-21 | ||
| Greece | 2023-01-31 | 2023-01-31 | 2023-10-21 | ||
| Hungary | 2022-03-03 | 2022-03-03 | 2023-10-21 | ||
| Iceland | 2022-11-09 | 2022-11-09 | 2023-10-21 | ||
| Italy | 2022-01-27 | 2022-01-27 | 2023-10-21 | ||
| Latvia | 2022-04-11 | 2022-04-11 | 2023-10-21 | ||
| Lithuania | 2022-01-10 | 2022-01-10 | 2023-10-21 | ||
| Netherlands | 2022-03-02 | 2022-03-02 | 2023-10-21 | ||
| Norway | 2022-09-12 | 2022-09-12 | 2023-10-21 | ||
| Poland | 2022-06-22 | 2022-06-22 | 2023-10-21 | ||
| Portugal | 2022-01-25 | 2022-01-25 | 2023-10-21 | ||
| Romania | 2022-07-12 | 2022-07-12 | 2023-10-21 | ||
| Slovakia | 2022-01-04 | 2022-01-04 | 2023-10-21 | ||
| Slovenia | 2022-05-25 | 2022-05-25 | 2023-10-21 | ||
| Spain | 2021-12-20 | 2021-12-28 | 2023-10-21 | ||
| Sweden | 2022-05-11 | 2022-05-11 | 2023-10-21 |
Results and documents
Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial
Documents 179 files
Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.
| Type | Title | Version |
|---|---|---|
| Protocol (for publication) | D1_Protocol - Signature Page_2024-510735-21-00_1_English_Red | 16Apr2025 |
| Protocol (for publication) | D1_Protocol_2024-510735-21-00 _1_English_Red | 03 |
| Protocol (for publication) | D1_Protocol_2024-510735-21-00 _1_Greek_Red | 03 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_CZ_English_NonRed | NA |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_ES_Spanish_NonRed | 20Jan2025 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_FR_English_Note to Assessor_NonRed | 18Feb2025 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_GR_English_NonRed | 1.1 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_IT_English_Note to Assesor_NonRed | 15Apr2025 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_NL_English_Note to Assesor_NonRed | v00 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_NO_English_NonRed | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_NO_English_Note to assessor_NonRed | 23Oct2024 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_PT_English_Note to Assesor_NonRed | 15Nov2024 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_1_SK_English_NonRed | 08Apr2025 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_Transition Replacement | NA |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements - Country_Transition Replacement | NA |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_Transition Replacement | v5.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_Transition Replacement | v5.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements - Country_Transition Replacement | NA |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_Transition Replacement | v5.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_Transition Replacement | NA |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_Transition Replacement | NA |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_Transition Replacement | v5.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_Transition Replacement | v5.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_Transition Replacement | NA |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements - Country_Transition Replacement | NA |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements-Country_Transition Replacement | NA |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements-Country_Transition Replacement | NA |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements-Country_Transition Replacement | NA |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_CZ_Czech_Red | 4.1 |
| Subject information and informed consent form (for publication) | L1_ICF - Additional Biomarkers_1_FR_French_Red | V01.01.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Country - Follow up for pregnant participant_1_BG_NonRed | 1.000 |
| Subject information and informed consent form (for publication) | L1_ICF - Country - Genetics_1_BG_Bulgarian_NonRed | 2.000 |
| Subject information and informed consent form (for publication) | L1_ICF - Country - Main ICF_1_BG_Bulgarian_Red | 4.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Country - Other_1_BG_Bulgarian_Red | 1.000 |
| Subject information and informed consent form (for publication) | L1_ICF - Data Protection - Adult_1_CZ_Czech_Red | 1.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Data Protection Adult EU GDPR_1_CZ_Czech_NonRed | 2.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_AT_German_NonRed | 1/1/2000 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_EE_Estonian_NonRed | v00.00.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_EE_Russian_NonRed | v00.00.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_ES_Spanish_NonRed | v.00.00.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_FI_Finnish_NonRed | 00.00.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_FR_French_NonRed | V00.00.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_GR_English_Red | v00.00.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_GR_Greek_Red | v00.00.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_HR_Croatian_NonRed | v00.00.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_IS_Icelandic_NonRed | 00.00.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_IT_Italian_NonRed | 00.00.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_NO_Norwegian_NonRed | v00.00.04 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_PT_Portuguese_NonRed | 01.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_SE_Swedish_NonRed | 1.1 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_SI_Slovenian_NonRed | 1.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_1_SK_Slovakian_NonRed | V1 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant participant_2_FR_French_NonRed | V00.00.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant partner of participant_1_EE_Estonian_NonRed | v00.00.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant partner of participant_1_EE_Russian_NonRed | v00.00.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant partner of participant_1_ES_Spanish_NonRed | v.00.00.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant partner of participant_1_FI_Finnish_NonRed | 00.00.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant partner of participant_1_HR_Croatian_NonRed | v00.00.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant partner of participant_1_IS_Icelandic_NonRed | 00.00.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for Pregnant Partner_1_DK_Danish_NonRed | 1.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up for pregnant partner_1_SE_Swedish_NonRed | 1.1 |
| Subject information and informed consent form (for publication) | L1_ICF - Follow up Pregnant Participant_1_DK_Danish_NonRed | 1.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetic Research Adult_1_DK_Danish_NonRed | 2.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetic Research PIS_1_HU_Hungarian_Red | 2.1 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetic Research_1_BE_Dutch_Red | 1.1 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetic Research_1_BE_English_Red | 1.1 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetic Research_1_BE_French_Red | 1.1 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetic Research_1_CZ_Czech_NonRed | 2.1 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetic Research_1_HU_Hungarian_NonRed | 2.1 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetic Research_2_CZ_Czech_Red | 2.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_AT_German_NonRed | 01.01.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_BG_Bulgarian_Red | 2.000 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_EE_Estonian_Red | v01.01.03 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_EE_Russian_Red | v01.01.03 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_ES_Spanish_Red | v01.01.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_GR_English_Red | v01.01.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_GR_Greek_Red | v01.01.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_HR_Croatian_NonRed | v01.01.03 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_IT_Italian_NonRed | 01.01.04 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_LT_Lithuanian_Red | 2.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_LT_Russian_Red | 2.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_LV_Latvian_Red | 2.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_LV_Russian_Red | 2.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_NL_Dutch_NonRed | v01010001 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_PT_Portuguese_Red | 02.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_RO_Romanian_Red | 2.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_SI_Slovenian_Red | 2.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Genetics_1_SK_Slovakian_NonRed | V1 |
| Subject information and informed consent form (for publication) | L1_ICF - Greenphire_1_FI_Finnish_NonRed | 08.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Info Sheet Female Partner_1_ES_Spanish_NonRed | v.00.00.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Info Sheet Female Partner_1_FI_Finnish_NonRed | 00.00.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Info Sheet Female Partner_1_NO_Norwegian_NonRed | 00.00.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_AT_German_NonRed | 03.03.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_DK_Danish_NonRed | 6.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_EE_Estonian_NonRed | 03.03.05 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_EE_Russian_NonRed | 03.03.05 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_ES_Spanish_NonRed | v03.03.05 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_FI_Finnish_NonRed | 03.03.05 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_FR_French_Red | V01.01.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_GR_English_Red | v02.02.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_GR_Greek_Red | v02.02.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_HR_Croatian_NonRed | 03.03.04 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_HU_Hungarian_NonRed | 6.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_HU_Hungarian_Red | 6.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_IS_Icelandic_NonRed | 03.03.04 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_IT_Italian_Red | 03.03.05 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_NL_Dutch_NonRed | 03030300 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_NO_English_Note to assessor_NonRed | 24Apr2025 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_NO_Norwegian_NonRed | v02.02.05 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_PT_Portuguese_NonRed | V04.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_SE_Swedish_NonRed | 4.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_SI_Slovenian_Red | 4.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_1_SK_Slovak_Red | 03.03.04.M |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_2_CZ_Czech_Red | 3.1 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_Addendum_1_FR_French_Red | V02.02.03 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF - Adult_Addendum_2_FR_French_NonRed | V03.03.04 |
| Subject information and informed consent form (for publication) | L1_ICF - Main ICF_1_RO_Romanian_NonRed | 4.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Main_1_BE_Dutch_Red | 5.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Main_1_BE_English_Red | 5.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Main_1_BE_French_Red | 5.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Optional Assessment - Coded data_1_HR_Croatian_NonRed | 03.03.04 |
| Subject information and informed consent form (for publication) | L1_ICF - Optional Assessment - Outside activities_1_HR_Croatian_NonRed | 03.03.02 |
| Subject information and informed consent form (for publication) | L1_ICF - Optional Assessment_1_ES_Spanish_Red | v01.00.00 |
| Subject information and informed consent form (for publication) | L1_ICF - Optional Assessment_1_IT_Italian_NonRed | 00.00.01 |
| Subject information and informed consent form (for publication) | L1_ICF - Optional Assessment_1_NL_Dutch_Red | v01010000 |
| Subject information and informed consent form (for publication) | L1_ICF - Other Adult - Optional Off-Site Visit_1_CZ_Czech_NonRed | 2.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Other Adult - Optional Offsite Visit_1_CZ_Czech_Red | 1.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Other Adult - Pregnant Participant_1_CZ_Czech_NonRed | 1.1 |
| Subject information and informed consent form (for publication) | L1_ICF - Other Adult_1_HU_Hungarian_Red | 1.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Other ICF - Adult Offsite_1_SE_Swedish_NonRed | 2.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Other_1_RO_Romanian_NonRed | 1.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Other_Mobile Application_1_LT_Lithuanian_Red | 1.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Other_Mobile Application_1_LT_Russian_Red | 1.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Pregnant Participant PIS_1_HU_Hungarian_NonRed | 1.1 |
| Subject information and informed consent form (for publication) | L1_ICF - Pregnant Participant_1_BE_Dutch_Red | 1.2 |
| Subject information and informed consent form (for publication) | L1_ICF - Pregnant Participant_1_BE_English_Red | 1.2 |
| Subject information and informed consent form (for publication) | L1_ICF - Pregnant Participant_1_BE_French_Red | 1.2 |
| Subject information and informed consent form (for publication) | L1_ICF - Pregnant Participant_1_HU_Hungarian_NonRed | 1.1 |
| Subject information and informed consent form (for publication) | L1_ICF - Pregnant Partner_1_BE_Dutch_Red | 1.2 |
| Subject information and informed consent form (for publication) | L1_ICF - Pregnant Partner_1_BE_English_Red | 1.2 |
| Subject information and informed consent form (for publication) | L1_ICF - Pregnant Partner_1_BE_French_Red | 1.2 |
| Subject information and informed consent form (for publication) | L1_ICF - Research ICF_1_DK_Danish_NonRed | 2.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Separate Data Protection Consent_1_ES_Spanish_NonRed | 15Apr2024 |
| Subject information and informed consent form (for publication) | L1_ICF - Separate Data Protection Consent_2_ES_Spanish_NonRed | 15Apr2024 |
| Subject information and informed consent form (for publication) | L1_ICF - Separate Data Protection Consent_Core_1_SK_Slovakian_NonRed | 03.03.02.M |
| Subject information and informed consent form (for publication) | L1_ICF - Separate Data Protection Consent_Pregnant_ Patient_1_SK_Slovakian_NonRed | 03.03.02.P |
| Subject information and informed consent form (for publication) | L1_ICF - Subject Information Sheet Female Partner_1_BE_Dutch_Red | 1.1 |
| Subject information and informed consent form (for publication) | L1_ICF - Subject Information Sheet Female Partner_1_BE_English_Red | 1.1 |
| Subject information and informed consent form (for publication) | L1_ICF - Subject Information Sheet Female Partner_1_BE_French_Red | 1.1 |
| Subject information and informed consent form (for publication) | L1_ICF - Subject Participation Card_1_HU_English_Red | 1.0 |
| Subject information and informed consent form (for publication) | L1_ICF - Subject Participation Card_1_HU_Hungarian_NonRed | 1.0 |
| Subject information and informed consent form (for publication) | L1_ICF Procedure_1_GR_English_NonRed | 1.1 |
| Subject information and informed consent form (for publication) | L1_ICF_Main ICF_1_LT_Lithuanian_Red | 4.0 |
| Subject information and informed consent form (for publication) | L1_ICF_Main ICF_1_LT_Russian_Red | 4.0 |
| Subject information and informed consent form (for publication) | L1_ICF_Main ICF_1_LV_Latvian_Red | 4.0 |
| Subject information and informed consent form (for publication) | L1_ICF_Main ICF_1_LV_Russian_Red | 4.0 |
| Subject information and informed consent form (for publication) | L1_ICF-Country ICF Genetic Research_1_PL_Polish_Red | 2.0 |
| Subject information and informed consent form (for publication) | L1_ICF-Country ICF Main_1_PL_Polish_Red | 5.0 |
| Subject information and informed consent form (for publication) | L1_ICF-Other Pregnant Participant_1_PL_Polish_NonRed | 1.0 |
| Subject information and informed consent form (for publication) | L1_ICF-Subject Info Sheet or Other Info_1_AT_German_Red | 6 |
| Subject information and informed consent form (for publication) | L2_ICF - Participant Transfer Authorization Form_1_BG_Bulgarian_NonRed | 3.0 |
| Subject information and informed consent form (for publication) | L2_ICF Procedure_1_ES_Spanish_NonRed | v02 |
| Subject information and informed consent form (for publication) | L2_ICF Procedure_1_FR_English_Note to Assessor_NonRed | 18Feb2025 |
| Subject information and informed consent form (for publication) | L2_ICF Procedure_1_PT_English_NonRed | V01 |
| Subject information and informed consent form (for publication) | L2_Patient Card_1_Czech_NonRed | 1.0 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2024-510735-21-00 _1_Norwegian_NonRed | 00 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2024-510735-21-00_1_Dutch_NonRed | v01 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2024-510735-21-00_1_English_NonRed | 02 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2024-510735-21-00_1_French_NonRed | V02 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2024-510735-21-00_1_Lithuanian_NonRed | v01 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2024-510735-21-00_1_Slovak_NonRed | v1 |
| Synopsis of the protocol (for publication) | D1_Protocol Summary in Lay Language_2024-510735-21-00_1_Swedish_NonRed | v01 |
| Synopsis of the protocol (for publication) | D1_Protocol_Protocol Summary in Technical Language_1_Bulgarian_NonRed | 02 |
| Synopsis of the protocol (for publication) | D1_Protocol_Protocol Summary in Technical Language_1_French_NonRed | V02 |
| Synopsis of the protocol (for publication) | D1_Protocol_Protocol Summary in Technical Language_1_Greek_NonRed | v02 |
| Synopsis of the protocol (for publication) | D1_Protocol_Protocol Summary in Technical Language_1_Italian_NonRed | 02.00 |
| Synopsis of the protocol (for publication) | D1_Protocol_Protocol Summary in Technical Language_1_Portuguese_NonRed | 03 |
| Synopsis of the protocol (for publication) | D1_Protocol_Protocol Summary in Technical Language_1_Spanish_NonRed | v02 |
| Synopsis of the protocol (for publication) | D1_Protocol_Protocol Summary in Technical Language_2024-510735-21-00_1_German_NonRed | v3 |
Application history
17 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2024-05-17 | Poland | Acceptable 2024-06-27
|
2024-06-27 |
| 2 | SUBSTANTIAL MODIFICATION | SM-2 | 2024-08-12 | Acceptable | 2024-11-05 | |
| 3 | SUBSTANTIAL MODIFICATION | SM-1 | 2024-09-23 | Acceptable | 2024-11-11 | |
| 4 | SUBSTANTIAL MODIFICATION | SM-3 | 2024-11-08 | 2025-01-21 | ||
| 5 | NON SUBSTANTIAL MODIFICATION | NSM-2 | 2025-01-22 | 2025-01-22 | ||
| 6 | NON SUBSTANTIAL MODIFICATION | NSM-3 | 2025-02-21 | Poland | 2025-02-21 | |
| 7 | NON SUBSTANTIAL MODIFICATION | NSM-4 | 2025-03-20 | Poland | 2025-03-20 | |
| 8 | SUBSTANTIAL MODIFICATION | SM-6 | 2025-05-15 | Poland | Acceptable 2025-08-25
|
2025-08-25 |
| 9 | NON SUBSTANTIAL MODIFICATION | NSM-6 | 2025-09-03 | Acceptable 2025-08-25
|
2025-09-03 | |
| 10 | NON SUBSTANTIAL MODIFICATION | NSM-7 | 2025-09-08 | Poland | Acceptable 2025-08-25
|
2025-09-08 |
| 11 | SUBSTANTIAL MODIFICATION | SM-10 | 2025-09-11 | Acceptable | 2025-09-30 | |
| 12 | SUBSTANTIAL MODIFICATION | SM-12 | 2025-09-11 | Acceptable | 2025-11-25 | |
| 13 | SUBSTANTIAL MODIFICATION | SM-11 | 2025-09-12 | Acceptable | 2025-12-08 | |
| 14 | SUBSTANTIAL MODIFICATION | SM-8 | 2025-09-19 | Acceptable | 2025-11-13 | |
| 15 | SUBSTANTIAL MODIFICATION | SM-7 | 2025-09-23 | Acceptable | 2025-12-12 | |
| 16 | SUBSTANTIAL MODIFICATION | SM-9 | 2025-09-24 | Acceptable | 2025-11-04 | |
| 17 | NON SUBSTANTIAL MODIFICATION | NSM-8 | 2026-01-30 | Acceptable | 2026-01-30 |